Domenico Magazzù

2.1k total citations · 1 hit paper
18 papers, 1.4k citations indexed

About

Domenico Magazzù is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Domenico Magazzù has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Domenico Magazzù's work include Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (4 papers) and HER2/EGFR in Cancer Research (4 papers). Domenico Magazzù is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (4 papers) and HER2/EGFR in Cancer Research (4 papers). Domenico Magazzù collaborates with scholars based in Italy, Russia and Spain. Domenico Magazzù's co-authors include Pinuccia Valagussa, Luca Gianni, Semiglazov Vf, Aňa Lluch, Brigitte Poirier, Young‐Hyuck Im, Ling‐Ming Tseng, Juan de la Haba-Rodríguez, Tadeusz Pieńkowski and José Luiz Pedrini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Domenico Magazzù

18 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

2016 555 citations Luca Gianni, Tadeusz Pieńkowski et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Domenico Magazzù Italy	12	905	570	320	219	133	18	1.4k
Soo Youn Cho South Korea	22	445 0.5×	320 0.6×	161 0.5×	237 1.1×	132 1.0×	70	1.2k
Hwa Kyung Byun South Korea	17	392 0.4×	209 0.4×	231 0.7×	243 1.1×	94 0.7×	84	910
Anastasia G Eleftheraki Greece	20	612 0.7×	240 0.4×	138 0.4×	316 1.4×	55 0.4×	37	1.2k
George Zogopoulos Canada	19	557 0.6×	275 0.5×	89 0.3×	182 0.8×	68 0.5×	54	975
Álvaro Taus Spain	18	540 0.6×	227 0.4×	81 0.3×	408 1.9×	74 0.6×	63	874
Mario Roncadin Italy	18	419 0.5×	474 0.8×	196 0.6×	347 1.6×	78 0.6×	64	1.1k
Guillermo Villacampa Spain	14	587 0.6×	264 0.5×	167 0.5×	327 1.5×	43 0.3×	90	1.1k
Giampaolo Biti Italy	22	449 0.5×	419 0.7×	271 0.8×	604 2.8×	127 1.0×	88	1.4k
Casey W. Williamson United States	13	376 0.4×	184 0.3×	94 0.3×	204 0.9×	163 1.2×	30	926
Navesh Sharma United States	16	465 0.5×	256 0.4×	198 0.6×	445 2.0×	96 0.7×	73	1.1k

Countries citing papers authored by Domenico Magazzù

Since Specialization

Citations

This map shows the geographic impact of Domenico Magazzù's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domenico Magazzù with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domenico Magazzù more than expected).

Fields of papers citing papers by Domenico Magazzù

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domenico Magazzù. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domenico Magazzù. The network helps show where Domenico Magazzù may publish in the future.

Co-authorship network of co-authors of Domenico Magazzù

This figure shows the co-authorship network connecting the top 25 collaborators of Domenico Magazzù. A scholar is included among the top collaborators of Domenico Magazzù based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Domenico Magazzù. Domenico Magazzù is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Necchi, Andrea, Domenico Magazzù, Andrea Anichini, et al.. (2016). An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).. Journal of Clinical Oncology. 34(2_suppl). 480–480. 15 indexed citations

Larkin, James, Brian I. Rini, Paul Nathan, et al.. (2016). Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma. Annals of Oncology. 27. vi266–vi266. 12 indexed citations

Necchi, Andrea, Andrea Anichini, Daniele Raggi, et al.. (2016). Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. Clinical Genitourinary Cancer. 14(4). 261–264.e4. 25 indexed citations

Gianni, Luca, Tadeusz Pieńkowski, Young‐Hyuck Im, et al.. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet Oncology. 17(6). 791–800. 555 indexed citations breakdown →

Gianni, Luca, Mauro Mansutti, Antonio Antón, et al.. (2016). ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.. Journal of Clinical Oncology. 34(15_suppl). 502–502. 11 indexed citations

Terenziani, Monica, Maura Massimino, Domenico Magazzù, et al.. (2015). Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer. European Journal of Cancer. 51(13). 1667–1674. 5 indexed citations

Bianchini, Giampaolo, Lajos Pusztai, Tadeusz Pieńkowski, et al.. (2015). Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Annals of Oncology. 26(12). 2429–2436. 95 indexed citations

Gianni, Luca, W. Eiermann, Semiglazov Vf, et al.. (2014). Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. 15(6). 640–647. 356 indexed citations

Bianchini, Giampaolo, Vera Cappelletti, Maurizio Callari, et al.. (2013). Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology. 31(15_suppl). 1014–1014. 3 indexed citations

10.

Gianni, Luca, W. Eiermann, Semiglazov Vf, et al.. (2013). Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 503–503. 11 indexed citations

11.

Zambetti, Milvia, José Baselga, W. Eiermann, et al.. (2013). Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. Journal of Clinical Oncology. 31(15_suppl). 537–537. 1 indexed citations

12.

Giles, Francis J., Gianantonio Rosti, Gert J. Ossenkoppele, et al.. (2011). A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Blood. 118(21). 2759–2759. 2 indexed citations

13.

Russo, Giuseppina, A. Di Benedetto, Domenico Magazzù, et al.. (2009). Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetologica. 48(2). 95–101. 24 indexed citations

14.

Seia, Manuela, Lucy Costantino, Valentina Paracchini, et al.. (2009). Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis. Clinical Biochemistry. 42(7-8). 611–616. 11 indexed citations

15.

Cohen, Richard B., Suzanne F. Jones, Margaret von Mehren, et al.. (2008). Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2520–2520. 11 indexed citations

16.

Panetta, Fabio, et al.. (2008). Diagnosis on a positive fashion of nonorganic failure to thrive. Acta Paediatrica. 97(9). 1281–1284. 4 indexed citations

17.

Squadrito, Giovanni, Teresa Pollicino, Irene Cacciola, et al.. (2006). Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 106(6). 1326–1330. 118 indexed citations

18.

Magazzù, Domenico, Mario Comelli, & Alessandra Marinoni. (2005). Are car drivers holding a motorcycle licence less responsible for motorcycle—Car crash occurrence?. Accident Analysis & Prevention. 38(2). 365–370. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact